Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Dyah A Perwitasari

Dyah A Perwitasari

Ahmad Dahlan University, Indonesia

Title: CYP2E1 polymorphism, acetylator profiles and drug-induced liver injury incidence of Indonesian tuberculosis patients

Biography

Biography: Dyah A Perwitasari

Abstract

Statement of the Problem: India, Indonesia and China had the largest number of cases from global total number (23%, 10% and 10%, respectively). There are large variations in the metabolism of the anti-tuberculosis drug-isoniazid, including polymorphisms of the NAT2 gene. This enzyme is markedly decreased in the livers of slow acetylators (SA). The elimination of INH follows a bimodal or trimodal distribution consisting of slow (SA), intermediate (IA) and rapid acetylators (RA). There is a strong correlation between these phenotypes and NAT2 genotypes in Caucasians. Previous studies have reported inconsistent results on whether slow or rapid acetylators are a risk factor for INH-induced hepatotoxicity. The purpose of this study is to determine the association between CYP2E1 polymorphisms and the development of DILI in Indonesians and determine the genotypes and phenotypes related to a change in the risk of DILI. 

Methodology & Theoretical Orientation: A cohort design consisting of 55 Indonesian adult tuberculosis (TB) patients was carried out. Acetylating phenotypes were studied using the metabolic ratio of plasma Ac HZ/HZ. DILI was defined using CTCAV version 4.0. The allelic and genotypic frequency distributions of CYP2E1 rs3813867 were studied using the polymerase chain reaction-amplification refractory mutation system (ARMS) methodology.

Findings: Patients with an INH concentration of more than 7 mg/mL showed a higher risk of developing DILI when compared with patients who showed. a therapeutic range of 3-6 mg/mL INH (OR: 1.3, 95% CI: 0.2-8.2). SAs had a higher incidence of DILI when compared with RAs (OR: 4.6, 95% CI: 1.3-15.9). Meanwhile, subjects with GC had a higher risk of DILI incidence (OR: 4.3, 95% CI: 0.8–24.4).

Conclusion & Significance: Our study shows that polymorphisms of CYP2E1 and SAs may have role in the DILI incidence. Recommendations are needed to be considered by the pharmacists during the adverse drug reaction monitoring.